Did you know?

Why the detection of lung cancer early is so important

When diagnosed early and resected immediately, a lung cancer patient's chance of survival in 10 years jumps to **92%**[1]

Lung cancer remains the **leading cause of cancer-related deaths** globally[2]

71% of all incidental lung nodules are not followed up and managed appropriately[3]

Delays in cancer screening due to the COVID-19 pandemic are thought to have caused **more than 95,000 additional** deaths from lung cancer worldwide[4]



Time to treatment matters because delays in initiating treatment are associated with up to **3% increased mortality for each week** that treatment is delayed[5]

Actionable incidental lung nodules show a **malignancy rate of 25%**[6]

CT screening reduces 10-year lung cancer mortality by **33% for women and 24% for men**, compared to no screening[7]



The cost of **treating late-stage cancer patients is 3x costlier** for hospitals and payers than treating cancers caught at an earlier stage[8]

Discover how Philips can help support your lung cancer program
www.philips.com/lungsolutions

1. International Early Lung Cancer Action Program Investigators. Survival of patients with stage 1 lung cancer detected on CT screening. N Engl J Med. 2006;355:1763- 1771 DOI: 10.1056/NEJMoa060476.
2. Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021.71:209-249. https://doi.org/10.3322/caac.21660
3. Blagev DP, et al. Follow-up of incidental pulmonary nodules and the radiology report. J Am Coll Radiol. 2014;11:378-83. DOI: 10.1016/j.jacr.2013.08.003.
4. Alkatout I, et al. Has COVID-19 affected cancer screening programs? A systematic review. Front Oncol. 2021. 11:675038. doi: 10.3389/fonc.2021.675038.
5. Khorana A, et al. Increase in time to initiating cancer therapy and association with worsened survival in curative settings: A U.S. analysis of common solid tumors. J Clin Oncol. 2017;35(15_suppl): 6557-6557. DOI: 10.1200/JCO.2017.35.15_suppl.6557.
6. Tanner NT, et al. Management of pulmonary nodules by community pulmonologists: a multicenter observational study. Chest. 2015 Dec;148(6):1405-1414. doi: 10.1378/chest.15-0630. PMID: 26087071; PMCID: PMC4665735.
7. Aberle DR, et al. The National Lung Screening Trial Research Team. Reduce lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. DOI: 10.1056/NEJMoa1102873.
8. Gildea et al. A retrospective analysis of delays in the diagnosis of lung cancer and associated costs. Clinicoecon Outcomes Res. 2017;9:261-269. DOI: 10.2147/CEOR.S132259.

www.philips.com/lungsolutions
4522 991 75691 * MAR 2022